login
login

Europe Daily Bulletin No. 12956

20 May 2022
Contents Publication in full By article 23 / 40
EU RESPONSE TO COVID-19 / Health
EMA begins formal evaluation of Valneva’s SARS-CoV-2 vaccine and is considering authorisation of Pfizer-BioNTech booster dose for children
Brussels, 19/05/2022 (Agence Europe)

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) began, on Wednesday 18 May, the formal scientific evaluation phase of the SARS-CoV vaccine developed by the firm Valneva, VLA200. The company was able to apply for a conditional marketing authorisation for its vaccine for adults aged 18 to 55.

This inactivated, adjuvanted whole virus Covid-19 vaccine, developed by Valneva, has been undergoing a progressive evaluation since 2 December 2021 (see EUROPE...

Contents

Russian invasion of Ukraine
EUROPEAN PARLIAMENT PLENARY
SECTORAL POLICIES
EU RESPONSE TO COVID-19
SOCIAL AFFAIRS - EMPLOYMENT
EXTERNAL ACTION
ECONOMY - FINANCE - BUSINESS
BREACHES OF EU LAW
NEWS BRIEFS